Literature DB >> 22898741

Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis.

Yu-Zhong Wang1, Mei Yan, Fa-Fa Tian, Jun-Mei Zhang, Qun Liu, Huan Yang, Wen-Bin Zhou, Jing Li.   

Abstract

Toll-like receptors (TLRs), the innate immunity components, have been demonstrated to participate in multiple autoimmune diseases. However, our knowledge of the roles of TLRs in myasthenia gravis (MG) is still scarce. In this study, we detected the mRNA expression of TLR1 to TLR10 in peripheral blood mononuclear cells (PBMCs) of MG patients and the healthy controls by quantitative real-time polymerase transcription chain reaction. Our data demonstrate that aberrant expressions of TLRs exist in the PBMCs of MG patients and of the total, expression level of TLR9 mRNA has significantly positive relation with the clinical severity of MG, which suggests that TLRs may be involved in the pathogenesis of MG.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22898741     DOI: 10.1007/s10753-012-9526-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

1.  Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis.

Authors:  T Sharshar; S Chevret; M Mazighi; P Chillet; G Huberfeld; C Berreotta; M Houfani; P Gajdos
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides.

Authors:  Rainald A Zeuner; Ken J Ishii; Martin J Lizak; Ihsan Gursel; Hiroshi Yamada; Dennis M Klinman; Daniela Verthelyi
Journal:  Arthritis Rheum       Date:  2002-08

Review 3.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

4.  MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.

Authors:  R Medzhitov; P Preston-Hurlburt; E Kopp; A Stadlen; C Chen; S Ghosh; C A Janeway
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

5.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

6.  Inactivation of TLR9 by a suppressive oligodeoxynucleotides can ameliorate the clinical signs of EAN.

Authors:  Yu-Zhong Wang; Qiu-Hua Liang; Hhoonisha Ramkalawan; Wei Zhang; Wen-Bin Zhou; Bo Xiao; Fa-Fa Tian; Huan Yang; Jing Li; Yong Zhang; Ning-An Xu
Journal:  Immunol Invest       Date:  2011-08-24       Impact factor: 3.657

Review 7.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

8.  Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

Authors:  Kol A Zarember; Paul J Godowski
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

9.  Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis.

Authors:  Monica Marta; Asa Andersson; Magnus Isaksson; Olle Kämpe; Anna Lobell
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

10.  Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation.

Authors:  Claire E McCoy; Susan Carpenter; Eva M Pålsson-McDermott; Linden J Gearing; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2008-03-20       Impact factor: 5.157

View more
  9 in total

1.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

Review 2.  Toll-like receptors and B cells: functions and mechanisms.

Authors:  Claire M Buchta; Gail A Bishop
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

3.  Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Authors:  Iris Dotan; Etgar Levy-Nissenbaum; Yehuda Chowers; Alexander Fich; Eran Israeli; Tomer Adar; Shimon Shteingart; Hermona Soreq; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

4.  Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.

Authors:  JunMei Zhang; Ge Jia; Qun Liu; Jue Hu; Mei Yan; BaiFeng Yang; Huan Yang; WenBin Zhou; Jing Li
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 5.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

6.  TIPE2 Play a Negative Role in TLR4-Mediated Autoimmune T Helper 17 Cell Responses in Patients with Myasthenia Gravis.

Authors:  Yong Zhang; Zhen Shao; Xiuying Zhang; Xiao Jia; Yan Xia; Yanyan Zhang; Ning Xin; Mingfeng Guo; Jing Chen; ShuangShuang Zheng; YuZhong Wang; Linlin Fu; Ruiguo Dong; Chenghua Xiao; Deqin Geng; Yonghai Liu
Journal:  J Neuroimmune Pharmacol       Date:  2015-10-24       Impact factor: 4.147

7.  Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.

Authors:  Ailian Du; Shiqian Huang; Xiaonan Zhao; Kuan Feng; Shuangyan Zhang; Jiefang Huang; Xiang Miao; Fulvio Baggi; Rennolds S Ostrom; Yanyun Zhang; Xiangjun Chen; Congfeng Xu
Journal:  Autophagy       Date:  2017-09-29       Impact factor: 16.016

Review 8.  Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.

Authors:  Haixia Li; Shan Liu; Jinming Han; Shengxian Li; Xiaoyan Gao; Meng Wang; Jie Zhu; Tao Jin
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

Review 9.  Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review.

Authors:  Omid Mirmosayyeb; Elham Moases Ghaffary; Mahsa Mazdak; Zahra Bagheri; Sara Bagherieh; Vahid Shaygannejad
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-17       Impact factor: 2.585

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.